Skip to content

Insider · CIK 0001871470

Harper Molly

director

Files at CPRX (CATALYST PHARMACEUTICALS, INC.). First filing Nov 29, 2024, latest Nov 29, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $385k sold

Signals

This insider’s open-market buys and sells, scored.

ScoreSideCompanyValueSharesHoldings changePrice contextFiled
51Moderatesell 5CPRX
CATALYST PHARMACEUTICALS, INC.
$385k17,500-100%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Dec 27, 2024CPRX
CATALYST PHARMACEUTICALS, INC.
MOption exercise
Common Stock, par value $0.001 per share
+1,333--2,746Dec 31, 2024
Dec 27, 2024CPRX
CATALYST PHARMACEUTICALS, INC.
MOption exercise
Restricted Stock Unitsderivative
-1,333$0.00$0131,274Dec 31, 2024
Dec 9, 2024CPRX
CATALYST PHARMACEUTICALS, INC.
MOption exercise
Common Stock, par value $0.001 per share
+1,413--1,413Dec 11, 2024
Dec 9, 2024CPRX
CATALYST PHARMACEUTICALS, INC.
MOption exercise
Restricted Stock Unitsderivative
-1,413$0.00$0132,607Dec 11, 2024
Nov 27, 2024CPRX
CATALYST PHARMACEUTICALS, INC.
MOption exercise
Common stock, par value $0.001 per share
+17,500$5.78$101k17,500Nov 29, 2024
Nov 27, 2024CPRX
CATALYST PHARMACEUTICALS, INC.
SOpen-market sale
Common stock, par value $0.001 per share
-17,500$22.00$385k0Nov 29, 2024
Nov 27, 2024CPRX
CATALYST PHARMACEUTICALS, INC.
MOption exercise
Options to purchase common stockderivative
-17,500$0.00$0134,020Nov 29, 2024
Nov 21, 2024CPRX
CATALYST PHARMACEUTICALS, INC.
AGrant or award
Options to purchase common stockderivative
+23,248$0.00$0148,679Nov 25, 2024
Nov 21, 2024CPRX
CATALYST PHARMACEUTICALS, INC.
AGrant or award
Restricted Stock Unitsderivative
+2,841$0.00$0151,520Nov 25, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.